Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims.

INTRODUCTION: Abrocitinib is approved for moderate-to-severe atopic dermatitis (AD) treatment. Real-world abrocitinib usage data are limited. The aim of this study was to characterize patients initiating abrocitinib in clinical settings in the United States. METHODS: Retrospective, observational study of patients aged ≥ 12 years with AD using linked claims (index date: abrocitinib initiation) and electronic health records in the OMNY Health real-world data platform (January 1, 2017-October 31, 2025). Baseline demographics, characteristics, comorbidities, medication history, and healthcare resource utilization were evaluated. Abrocitinib dose changes ≤ 12 months post-index, early persistence (prescription refill within 60 days of index), and AD severity changes from baseline were assessed. RESULTS: Overall, 401 patients initiated abrocitinib (8.5% adolescent; 91.5% adult). Mean time since diagnosis was 4.2 years. Most patients (72.1%) received abrocitinib as their first advanced systemic therapy and the most common starting dose was 100 mg (81.8%). The most frequent pre-index AD therapy overall was topical treatment (72.6%). Within 12 months post-index, 90.8% of patients remained on the starting dose and 60.8% demonstrated early persistence. CONCLUSION: Most patients with moderate-to-severe AD prescribed abrocitinib receive 100 mg as the starting dose, refill their prescription within 60 days of index, and maintained their starting dose. Limitations include incomplete patient data and lack of generalizability to other settings.